Page last updated: 2024-08-17

mannitol and Melanoma

mannitol has been researched along with Melanoma in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19905 (22.73)18.7374
1990's0 (0.00)18.2507
2000's12 (54.55)29.6817
2010's3 (13.64)24.3611
2020's2 (9.09)2.80

Authors

AuthorsStudies
Balan, S; Bhardwaj, N; Blazquez, AB; Gimenez, G; Gnjatic, S; Holman, RM; Lattanzi, M; Mandeli, J; Marron, TU; McClain, CB; Meseck, M; Ott, PA; Pavlick, A; Sabado, RL; Salazar, AM1
Koeppel, AF; Kumar, P; Lynch, KT; Mauldin, IS; Melssen, MM; Meneveau, MO; Pollack, KE; Slingluff, CL; Sol-Church, K; Turner, S; Young, SJ1
Clancy-Thompson, E; King, LK; Mullins, DW; Mullins, IM; Nunnley, LD; Slingluff, CL1
Adams, S; Bhardwaj, N; Chiriboga, L; Cruz, CM; Darvishian, F; Escalon, J; Escano, C; Gnjatic, S; Goldberg, J; Hasan, F; Holman, RM; Jungbluth, A; Mandeli, J; Muren, C; Ott, PA; Pan, L; Pavlick, A; Rolnitzsky, L; Sabado, RL; Sharpe, D; Spadaccia, M; Vasilakos, JP; Vengco, I; Venhaus, R; Yepes, E1
Andrade Filho, PA; Donnenberg, A; Fourcade, J; Janjic, B; Kirkwood, JM; Krieg, A; Kudela, P; Land, SR; Sander, C; Shen, H; Zarour, HM1
Altorki, NK; Bender, A; Ferrara, CA; Gnjatic, S; Hoffmann, E; Jäger, E; Karbach, J; Neumann, A; Old, LJ; Weidmann, E; Yuan, J1
HUMBLE, JG; NEWTON, KA; PEGG, DE; SKINNER, ME; WESTBURY, G1
Barnd, DL; Chianese-Bullock, KA; Deacon, DH; Eastham, S; Engelhard, VH; Galavotti, H; Gibson, J; Grosh, WW; Hibbitts, S; Merrill, P; Neese, PY; Patterson, JW; Petroni, GR; Ross, M; Slingluff, CL; Teates, D; Wiernasz, CJ; Woodson, EM; Yamshchikov, GV1
Collins, S; Coventry, B; Farrelly, M; Hersey, P; Hirst, D; Johnson, H; Menzies, SW; Nguyen, T1
Dranoff, G1
Davis, T; Groshen, S; Keler, T; Lee, P; Liu, D; Nichol, G; Sanderson, K; Scotland, R; Sian, S; Snively, J; Weber, J; Yellin, M1
Bissonette, EA; Chianese-Bullock, KA; Fink, R; Garbee, C; Grosh, WW; Hibbitts, S; Merrill, P; Murphy, C; Neese, PY; Patterson, JW; Petroni, GR; Pressley, J; Slingluff, CL; Wiernasz, CJ; Woodson, EM; Yamshchikov, G1
Allred, JB; Celis, E; Creagan, ET; Ingle, JN; Kaur, JS; Loprinzi, CL; Markovic, SN; Nevala, WK; Pitot, HC; Pittelkow, MR; Rao, RD; Suman, VJ1
Celis, E1
Alonso, D; Anasagasti, L; Arango, Mdel C; Carr, A; Fernández, LE; Gómez, E; González, J; González, JL; Gracia, E; Joan, A; Melgares, Mde L; Noris, E; Osorio, M; Pérez, R; Rengifo, E; Rodríguez, E; Saurez, G; Torres, I; Torriella, A1
Atkins, MB; Carrillo, C; Clark, JI; Crosby, NA; Dutcher, J; Ernstoff, MS; Flaherty, L; Gollob, J; Kirkwood, JM; LaFleur, B; Margolin, KA; Mier, J; O'Boyle, K; Panka, DJ; Sosman, JA; Urba, WJ1
Al-Sarraf, M; Balducci, L; Fletcher, W; Hewlett, JS; McCracken, J; Oishi, N; Padilla, F; Pugh, R1
Barth, RF; Bartus, RT; Coderre, JA; Ferketich, AK; Moeschberger, ML; Nawrocky, MM; Rofstad, EK; Rotaru, JH; Yang, W1
Batard, P; Cerottini, JC; Guillaume, P; Liénard, D; Pittet, MJ; Rimoldi, D; Romero, P; Speiser, DE1
Swanson, TL1
Keogh, JA; Lamb, JD1
Barnett, PA; Brown, P; Dahlborg, SA; Eckerman, KF; Hellström, I; Hellström, KE; Larson, SM; Miley, A; Neuwelt, EA; Specht, HD1

Trials

11 trial(s) available for mannitol and Melanoma

ArticleYear
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Cancer immunology research, 2020, Volume: 8, Issue:1

    Topics: Adjuvants, Immunologic; Aged; Antigens, Neoplasm; Cancer Vaccines; Carboxymethylcellulose Sodium; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Priming; Female; Humans; Immunity, Cellular; Immunity, Humoral; Interferon Inducers; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Patient Safety; Poly I-C; Polylysine; Skin Neoplasms; Treatment Outcome

2020
Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
    Cancer immunology research, 2013, Volume: 1, Issue:5

    Topics: Amino Acid Sequence; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Mannitol; Melanoma; Molecular Sequence Data; Neoplasm Proteins; Oleic Acids; Peptides; Receptors, CXCR3

2013
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Cancer immunology research, 2015, Volume: 3, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Imidazoles; Immunity, Cellular; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Peptide Fragments; Vaccination

2015
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Cancer Vaccines; CD8-Positive T-Lymphocytes; Female; Humans; Immunization; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Proteins; Oleic Acids; Oligodeoxyribonucleotides; Peptide Fragments; Pilot Projects; Skin Neoplasms; T-Lymphocytes, Cytotoxic

2008
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-01, Volume: 21, Issue:21

    Topics: Adult; Aged; Cancer Vaccines; Dendritic Cells; Drug Administration Schedule; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Lymph Nodes; Male; Mannitol; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Radiography; Skin Neoplasms; Survival Analysis; T-Lymphocytes; Thoracic Neoplasms; Treatment Outcome

2003
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
    Cancer immunology, immunotherapy : CII, 2005, Volume: 54, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Cytokines; Enzyme-Linked Immunosorbent Assay; Epitopes; Epitopes, T-Lymphocyte; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Immunotherapy; Inflammation; Interferon-gamma; Lymphocytes; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Peptides; Skin Neoplasms; Time Factors; Treatment Outcome

2005
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    American journal of clinical oncology, 2006, Volume: 29, Issue:4

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Cancer Vaccines; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Hypersensitivity, Delayed; Immunophenotyping; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Vaccines, Subunit

2006
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Amino Acid Sequence; Cancer Vaccines; Dendritic Cells; Epitopes; Female; Freund's Adjuvant; Granulocyte-Macrophage Colony-Stimulating Factor; HLA Antigens; Humans; Lymphocyte Activation; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Staging; Oleic Acids; Oligopeptides; Skin Neoplasms; Survival Analysis; Survival Rate; T-Lymphocytes, Cytotoxic; Treatment Outcome

2007
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Adult; Aged; Bacterial Outer Membrane Proteins; Cancer Vaccines; Eye Neoplasms; Female; G(M3) Ganglioside; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Liposomes; Male; Mannitol; Melanoma; Middle Aged; Neisseria meningitidis; Oleic Acids; Skin Diseases; Survival Analysis; Treatment Outcome; Vaccination; Vitiligo

2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; gp100 Melanoma Antigen; HLA-A2 Antigen; Humans; Interleukin-2; Male; Mannitol; Melanoma; Membrane Glycoproteins; Middle Aged; Oleic Acids

2008
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
    Cancer treatment reports, 1982, Volume: 66, Issue:1

    Topics: Cisplatin; Humans; Kidney Diseases; Mannitol; Melanoma; Water-Electrolyte Balance

1982

Other Studies

11 other study(ies) available for mannitol and Melanoma

ArticleYear
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
    Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:1

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Arginase; Biopsy; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD40 Ligand; Clinical Trials, Phase I as Topic; Female; Freund's Adjuvant; Humans; Immunization, Secondary; Immunogenicity, Vaccine; Injections, Intralesional; Lipids; Male; Mannitol; Melanoma; Middle Aged; Oleic Acids; Randomized Controlled Trials as Topic; Signal Transduction; Skin; Skin Neoplasms; Th1 Cells; Toll-Like Receptors; Tumor Microenvironment; Vaccination; Vaccines, Subunit; Young Adult

2020
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    International journal of cancer, 2010, Feb-15, Volume: 126, Issue:4

    Topics: Antigens, Neoplasm; Breast Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunotherapy; Mannitol; Melanoma; Membrane Proteins; Neoplasm Staging; Neoplasms; Oleic Acids; Oligodeoxyribonucleotides; Ovarian Neoplasms; Sarcoma; Vaccination

2010
Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement.
    Lancet (London, England), 1959, May-09, Volume: 1, Issue:7080

    Topics: Antineoplastic Agents; Bone Marrow; Cytotoxins; Mannitol; Mechlorethamine; Melanoma; Nitrogen Mustard Compounds; Vegetables

1959
CTLA-4 blockade: unveiling immune regulation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Autoimmunity; Cancer Vaccines; CTLA-4 Antigen; Humans; Mannitol; Melanoma; Oleic Acids

2005
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antigens, Neoplasm; Autoimmunity; Cancer Vaccines; CTLA-4 Antigen; Female; Flow Cytometry; gp100 Melanoma Antigen; Humans; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Neoplasm Staging; Oleic Acids; Peptide Fragments; Receptors, CCR; Receptors, Chemokine; Vaccination

2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Mar-01, Volume: 174, Issue:5

    Topics: Adjuvants, Immunologic; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; Cytotoxicity Tests, Immunologic; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymph Nodes; Mannitol; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Protein Binding; Vaccines, Combined; Vaccines, Subunit

2005
Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine.
    International journal of radiation oncology, biology, physics, 2002, Mar-01, Volume: 52, Issue:3

    Topics: Animals; Blood-Brain Barrier; Boron Compounds; Boron Neutron Capture Therapy; Bradykinin; Brain Neoplasms; Humans; Mannitol; Melanoma; Osmosis; Phenylalanine; Radiation-Sensitizing Agents; Rats; Rats, Nude

2002
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    European journal of immunology, 2002, Volume: 32, Issue:3

    Topics: Adjuvants, Immunologic; Antigens, Neoplasm; Antigens, Viral; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Differentiation; Cytomegalovirus; HLA-A2 Antigen; HLA-DR Antigens; Humans; Immunologic Memory; Immunotherapy; Influenza A virus; Lymphocyte Activation; Mannitol; MART-1 Antigen; Melanoma; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Vaccines, Subunit; Viral Matrix Proteins

2002
The growth response of cells in medium made hyperosmolal with electrolytes or mannitol.
    Journal of cellular physiology, 1979, Volume: 101, Issue:1

    Topics: Carcinoma, Transitional Cell; Cell Division; Cell Line; Cells, Cultured; Culture Media; Humans; Lymphocytes; Mannitol; Melanoma; Osmolar Concentration; Potassium Chloride; Sodium Chloride; Urinary Bladder Neoplasms

1979
Anaphylactoid reaction to mannitol.
    Canadian Anaesthetists' Society journal, 1979, Volume: 26, Issue:5

    Topics: Adolescent; Anaphylaxis; Drug Hypersensitivity; Edema; Eye Neoplasms; Humans; Male; Mannitol; Melanoma; Respiratory Insufficiency

1979
Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.
    Neurosurgery, 1987, Volume: 20, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Blood-Brain Barrier; Brain Neoplasms; Humans; Mannitol; Melanoma

1987